Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2026-01-16 @ 3:26 PM
Study NCT ID:
NCT03443869
Status:
COMPLETED
Last Update Posted:
2023-07-28
First Post:
2018-02-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
8228-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None